FY2023 NIH awards · Principal investigators

Pharmacology at Creighton University

Omaha, NE

Funding

$1.4M

$1,410,345

Awards

6

FY2023 NIH awards in Pharmacology

Principal investigators

5

5 lead a grant here, 0 co-investigators

Department rank

#104

of 143 · Ranking

NIH names only the principal investigators on an award, so this page lists only them. The department is the award's: it is where ScienceDex counts the award, not a list of the department's members.
These are the awards in the Pharmacology row of the Creighton University page.

Leads a grant in this department

5 contact PIs of these awards, by the funding they lead. Other principal investigators on an award are listed with it and under Co-investigators.

Tu, Yaping
Leads 1 award · $411,112
- 1R01HL164593-01A1Department: NIH department code
  A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
  $411,112
  award amount
Teitz, Tal
Leads 1 award · $402,857
- 5R01DC018850-03Department: NIH department code
  Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss
  $402,857
  award amount
Simeone, Kristina A
Leads 1 award · $359,779
- 5R01NS126418-02Department: NIH department code
  Autoresuscitation and SUDEP
  $359,779
  award amount
Dravid, Shashank Manohar
Leads 2 awards · $181,940
- 5R01NS118731-04Department: NIH department code
  Trans-synaptic signaling complex in amygdala pain mechanisms
  $137,354
  award amount
- 1R21NS132590-01Department: NIH department code
  Structure-Function and Signaling of Glutamate Delta 1 in Pain Mechanism
  $44,586
  award amount
Ingersoll, Matthew A
Leads 1 award · $54,657
- 5F32DC020102-02Department: NIH department code
  Repurposing FDA-Approved MEK Inhibitor Trametinib for Protection Against Cisplatin-Induced Hearing Loss
  $54,657
  award amount